A BBB penetrating “Chokepoint” inhibitor

AUM003 inhibits activity of the serine/threonine kinases MNK1/MNK2 and down-regulates eukaryotic translation initiation factor 4E (eIF4E) by down regulating S209 phosphorylation on eIF4E by MNK1 and MNK2. Thus, by preventing the phosphorylation of eIF4E, MNK inhibition could provide a viable therapeutic approach in high-eIF4E dependent cancers, neurodevelopmental disorders, and psychiatric disorders.

AUM003 is a Blood brain barrier penetrant with strong monotherapy activity in various cancers.